187724-91-0

Upstream product

• 141-52-6 sodium ethanolate 
• 57508-48-2 carbethoxyacetamidine hydrochloride 
• 81590-55-8 ethyl 4-(2-bromoacetyl)benzoate 
• 2318-25-4 ethyl 3-ethoxy-3-iminopropanoate hydrochloride 
• 105-56-6 ethyl 2-cyanoacetate 

Downstream Products

• 187724-93-2 4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-6-yl)benzoic acid ethyl ester 
• 187724-92-1 ethyl 4-(4-hydroxy-7H-pyrrolo[2,3-d]pyrimidin-6-yl)benzoate 

Relevant academic research and scientific papers

Synthesis and cholinesterase inhibition activity of new pyrrolopyrimidine derivatives

Cholinesterase plays a vital role in the decline of cholinergic transmission and thus can contribute to the development of Alzheimer's disease (AD). Thus, compounds that can inhibit acetylcholinesterase (AChe) and butyrylcholinesterase (BuChe) are the potential drugs for the treatment of AD. A series of novel pyrrolopyrimidine derivatives was synthesized and evaluated for their inhibitory activity against cholinesterase by Ellman method. Among the ten newly synthesized compounds, 4-(4-((4-(difluoromethoxy)phenyl)amino)-7H-pyrrolo [2,3-d]pyrimidin-6-yl)benzoate was the most potent molecule identified with the IC50 values of 18 μM and 17 uM on AChe and BuChe respectively.

Pyrrolopyrimidines and processes for the preparation thereof

PCT No. PCT/EP96/02728 Sec. 371 Date Jan. 26, 1998 Sec. 102(e) Date Jan. 26, 1998 PCT Filed Jun. 24, 1996 PCT Pub. No. WO97/02266 PCT Pub. Date Jan. 23, 1997Described are 7H-pyrrolo[2,3-d]pyrimidine derivatives of formula I wherein the symbols are as defined in claim 1. Those compounds inhibit tyrosine protein kinase and can be used in the treatment of hyperproliferative diseases, for example tumour diseases.